Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma is expected to have a positive outlook due to its strong pipeline of drugs targeting a novel mechanism through the A3 adenosine receptor, which is highly expressed in cancer and inflammatory cells. Their latest results in mPDAC demonstrate strong potential, and with multiple drugs in Phase II and III trials, it appears that Can Fite has a diverse portfolio that mitigates some risk. Additionally, with a discounted cash flow analysis and net pro forma cash added, the valuation of Can Fite looks promising. However, risks such as competition and dilution should be considered.

Bears say

Can Fite Biopharma is in a challenging financial situation as it reported FY2025 revenues of only $405K and a net loss of $5.97 per diluted share. Despite some favorable clinical data in its Phase 2a study for pancreatic cancer, the company will need significant funding to pursue its combination immunotherapy strategy for the indication and has no revenues projected for 2026. Management has disclosed confidentiality agreements for potential partnerships, but until a partnership is secured, Can Fite Biopharma's financial outlook remains uncertain and reliant on additional capital raises.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.